Workflow
CNS Pharmaceuticals(CNSP)
icon
Search documents
CNS Pharmaceuticals(CNSP) - 2023 Q4 - Annual Results
2024-04-01 21:01
[Filing Information](index=1&type=section&id=Filing%20Information) This section details the registrant's identification, incorporation jurisdiction, emerging growth status, and registered securities [Registrant and Filing Details](index=1&type=section&id=Registrant%20and%20Filing%20Details) This section provides the basic identification details for CNS Pharmaceuticals, Inc. as the registrant, including its address, jurisdiction, and confirmation of its status as an emerging growth company - Registrant: **CNS Pharmaceuticals, Inc.**[1](index=1&type=chunk) - Jurisdiction of Incorporation: **Nevada**[1](index=1&type=chunk) - Emerging Growth Company Status: **Yes**[3](index=3&type=chunk) [Securities Registered](index=1&type=section&id=Securities%20Registered) The company's common stock is registered on The NASDAQ Stock Market LLC under the trading symbol CNSP | Title of each class | Trading Symbols(s) | Name of each exchange on which registered | | :------------------ | :----------------- | :---------------------------------------- | | Common stock, par value $0.001 per share | CNSP | The NASDAQ Stock Market LLC | [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) CNS Pharmaceuticals, Inc. announced its financial results for the period ended December 31, 2023, and recent operational highlights through a press release issued on April 1, 2024. This press release is incorporated by reference as Exhibit 99.1 - Company issued a press release on **April 1, 2024**, announcing financial results for the period ended **December 31, 2023**, and recent operational highlights[5](index=5&type=chunk) - The press release is attached to this report as **Exhibit 99.1** and is incorporated by reference[5](index=5&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section details the financial statements and exhibits filed with the report, including the press release and interactive data file [Exhibits List](index=2&type=section&id=Exhibits%20List) This section lists the exhibits filed with the Form 8-K, including the press release detailing financial results and the interactive data file | Exhibit No. | Exhibit Description | | :------------ | :---------------------------------------------------------- | | 99.1 | Press release dated April 1, 2024 | | 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) | [Signature](index=3&type=section&id=Signature) The report was duly signed on behalf of CNS Pharmaceuticals, Inc. by Chris Downs, Chief Financial Officer, on April 1, 2024, in accordance with the Securities Exchange Act of 1934 requirements - Report signed by **Chris Downs**, Chief Financial Officer of **CNS Pharmaceuticals, Inc.**[10](index=10&type=chunk) - Date of signature: **April 1, 2024**[10](index=10&type=chunk)
CNS Pharmaceuticals(CNSP) - 2023 Q4 - Annual Report
2024-04-01 21:00
We will continue to require substantial additional capital to continue our clinical development and commercialization activities. Because successful development of our product candidates is uncertain, we are unable to estimate the actual amount of funding we will require to complete research and development and commercialize our products under development. · whether our plan for clinical trials will be completed on a timely basis; · the costs associated with securing and establishing commercialization and m ...
CNS Pharmaceuticals(CNSP) - 2023 Q3 - Quarterly Report
2023-11-13 16:00
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Name of registrant as specified in its charter) Nevada 82-2318545 (Stat ...
CNS Pharmaceuticals(CNSP) - 2023 Q2 - Quarterly Report
2023-08-13 16:00
We do not have manufacturing facilities and all manufacturing activities are contracted out to third parties. Additionally, we do not have a sales organization. On June 10, 2020, the FDA granted Orphan Drug Designation ("ODD") for Berubicin for the treatment of malignant gliomas. ODD from the FDA is available for drugs targeting diseases with less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval of a NDA in the United States. During that period the FDA gene ...
CNS Pharmaceuticals(CNSP) - 2023 Q1 - Quarterly Report
2023-05-14 16:00
In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section entitled "Risk Factors" in our 2022 Annual Report on Form 10-K, filed with the SEC, which are incorporated herein by reference, as well as the additional risk factors set forth below. The risks described in such reports are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materi ...
CNS Pharmaceuticals (CNSP) Investor Presentation - Slideshow
2023-04-06 18:11
| --- | --- | --- | --- | |--------------|-------|-------|------------------------------------------------------------------------------------| | | | | | | | | | | | NASDAQ: CNSP | | | | | | | | | | April 2023 | | | www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 | Forward-Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward-looking statements. All statements contained herein other than statements of historica ...
CNS Pharmaceuticals(CNSP) - 2022 Q4 - Annual Report
2023-03-30 16:00
On June 10, 2020, the FDA granted Orphan Drug Designation ("ODD") for Berubicin for the treatment of malignant gliomas. ODD from the FDA is available for drugs targeting diseases with less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval of a NDA in the United States. During that period the FDA generally could not approve another product containing the same drug for the same designated indication. Orphan drug exclusivity will not bar approval of another pro ...
CNS Pharmaceuticals(CNSP) - 2022 Q3 - Quarterly Report
2022-11-09 16:00
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Name of registrant as specified in its charter) Nevada 82-2318545 (Stat ...
CNS Pharmaceuticals (CNSP) Investor Presentation - Slideshow
2022-08-20 14:58
| --- | --- | --- | |--------------|-------|------------------------------------------------------------------------------------| | | | | | | | | | NASDAQ: CNSP | | | | | | | | August 2022 | | www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946-9185 | 2 Forward-Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward-looking statements. All statements contained herein other than statements of historical fact, including sta ...
CNS Pharmaceuticals(CNSP) - 2022 Q2 - Quarterly Report
2022-08-11 16:00
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ______________ Commission file number: 001-39126 CNS Pharmaceuticals, Inc. (Name of registrant as specified in its charter) Nevada 82-2318545 (State or ...